Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta

@article{strm2002BeneficialEO,
  title={Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta},
  author={Eva {\AA}str{\"o}m and Stefan S{\"o}derh{\"a}ll},
  journal={Archives of Disease in Childhood},
  year={2002},
  volume={86},
  pages={356 - 364}
}
Aim: To find an effective symptomatic treatment for osteogenesis imperfecta (OI). Methods: In a prospective observational study disodium pamidronate (APD) was given as monthly intravenous infusions to 28 children and adolescents (aged 0.6–18 years) with severe OI or a milder form of the disease, but with spinal compression fractures. Results: During treatment for 2–9 years, dual energy x ray absorptiometry measurements of the total body and of the lumbar spine showed a gradual increase in bone… Expand

Paper Mentions

Interventional Clinical Trial
This is a Phase 2, open-label, randomized, controlled clinical study of pediatric subjects treated with pamidronate with calcium and vitamin D versus calcium and vitamin D alone… Expand
ConditionsOsteopenia, Osteoporosis
InterventionDrug
Zoledronic Acid Treatment in Children with Osteogenesis Imperfecta
TLDR
Intravenous zoledronic acid is an effective mode of treatment in children with OI and the treatment response is comparable to pamidronate but the infusion protocol is more convenient. Expand
Pamidronate Treatment of Children with Moderate-to-Severe Osteogenesis Imperfecta: A Note of Caution
TLDR
Pamidronate with physiotherapy and orthopedic management improved outcomes without delaying fracture healing in 19 (70%) of 27 patients, and should be reserved for severe OI with multiple fractures and/or flattened vertebras. Expand
Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta
TLDR
APD is an efficient symptomatic treatment for infants with severe osteogenesis imperfecta, but additional orthopaedic surgery is often needed, and long-term follow-up is important. Expand
Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
TLDR
The results support the findings of Glorieux et al that cyclic administration of intravenous pamidronate in children with OI has beneficial effects with respect to BMD z scores and physical disability. Expand
Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
TLDR
Bisphosphonate seems to be an effective symptomatic treatment for children with osteogenesis imperfecta irrespective of severity of mutation or clinical phenotype and has a positive effect on fracture rate, BMD, mobility score, wellbeing and pain episode. Expand
Oral bisphosphonate treatment for osteogenesis imperfecta—an Indian perspective
TLDR
Oral alendronate is associated with a lower fracture rate, improvement in BMD and a decrease in hypercalciuria after a median of 9.5 months of treatment, according to a retrospective analysis of pre- and post-treatment changes. Expand
Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age
TLDR
Treatment with intravenous pamidronate is safe, significantly improves lumbar bone mineral density (L-BMD), and reduces fracture rates in young infants with OI while preserving linear growth. Expand
Bisphosphonate treatment of children and adolescents with osteogenesis imperfecta : Effects on clinical symptoms and bone turnover
TLDR
APD is an effective symptomatic treatment of children and adolescents with severe OI and milder forms with vertebral compression fractures and less pain and improved well-being during treatment, and bone turnover markers cannot predict vertebral compressions, mobility or pain. Expand
Experience With Bisphosphonates in Osteogenesis Imperfecta
TLDR
It seems clear that the benefits of pamidronate therapy outweigh its potential risks in moderate-to-severe osteogenesis imperfecta, and it has become the standard of care for patients with this condition. Expand
Cyclic Pamidronate Therapy in Children with Osteogenesis Imperfecta: Results of Treatment and Follow-up After Discontinuation
BACKGROUND Cyclic intravenous pamidronate treatment is widely used for symptomatic therapy of osteogenesis imperfecta (OI). However, data after discontinuation are very limited. AIM The results ofExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta
TLDR
It is indicated that APD is of value in the symptomatic treatment of children with severe OI and a major improvement in well‐being, pain and activities of daily life is reported. Expand
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
TLDR
In children with severe osteogenesis imperfecta, cyclic administration of intravenous pamidronate improved clinical outcomes, reduced bone resorption, and increased bone density. Expand
Bisphosphonates in Children with Osteogenesis Imperfecta may Improve Bone Mineralization but not Bone Strength. Report of Two Patients
TLDR
Two patients studied by bone dual energy X-ray absorptiometry (DEXA), and recently by peripheral quantitative computerized tomography (pQCT), provide quantitative assessments of volumetric bone density and of architectural variables such as bone diaphyseal area or cross-sectional moments of inertia. Expand
Therapy of osteogenesis imperfecta with synthetic salmon calcitonin.
TLDR
Long-term administration of synthetic salmon calcitonin may be beneficial to young children with osteogenesis imperfecta and congenita and there was a significant improvement in radiographic bone density in patients under 5 years of age. Expand
Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.
TLDR
Pamidronate treatment in severely affected OI patients under 3 yr of age is safe, increases BMD, and decreases fracture rate, and no adverse side-effects were noted. Expand
Intravenous pamidronate treatment in osteogenesis imperfecta.
TLDR
Three children with osteogenesis imperfecta, severe osteopenia, and repeated fractures were treated with cyclic infusions of aminohydroxypropylidene bisphosphonate (pamidronate) for a period ranging from 22 to 29 months, with a striking reduction of new fracture episodes and a marked improvement in the quality of the patients' lives. Expand
Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate)
TLDR
Preliminary but long-term obser- vations suggest that the bisphosphonate olpadronate may be a useful treatment for patients with OI and vertebral fractures. Expand
Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta
TLDR
A 12-year-old female suffering fromosteogenesis imperfecta was treated with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate orally, 250 mg daily, for periods of 2 months, alternating with periods of2 months of abstinence, and X-rays of the bones showed large, parallel radio-opaque striae corresponding exactly to the periods of therapy. Expand
Just taller or more bone? The impact of growth hormone on osteogenesis imperfecta and idiopathic juvenile osteoporosis.
TLDR
It is concluded that GH in IJO should currently be used only for research and not in clinical practice, because it is difficult to differentiate the effects of GH therapy from those of puberty. Expand
Just taller or more bone? The impact of growth hormone on osteogenesis imperfecta and idiopathic juvenile osteoporosis.
  • N. Wright
  • Medicine
  • Journal of pediatric endocrinology & metabolism : JPEM
  • 2000
TLDR
It is concluded that GH in IJO should currently be used only for research and not in clinical practice, because it is difficult to differentiate the effects of GH therapy from those of puberty. Expand
...
1
2
3
4
5
...